GHRP-2: A diagnostic peptide with thin therapeutic evidence

GHRP-2 is one of those compounds with a real but narrow medical use that has been stretched far past what the evidence supports. In Japan it is an approved diagnostic tool: one dose triggers a measurable spike in growth hormone, which helps doctors check whether someone is making too little of it. Online, the same peptide gets sold as a “research chemical” and hyped for muscle gain, fat loss, recovery, and anti-aging — none of which is backed by trials that measured those outcomes. This profile keeps those two stories apart.

What it is

GHRP-2, also called pralmorelin, is a synthetic hexapeptide — a short chain of six amino acids (the building blocks that make up proteins). Its molecular formula is C45H55N9O6, with a molecular weight of about 817.97 g/mol (PubChem CID 5493556, the acetate salt; free pralmorelin is CID 6918245). The chain includes several D-amino acids (mirror-image versions of normal amino acids) and an unusual naphthylalanine residue. Those tweaks help it shrug off the enzymes that would normally chop a peptide apart, and they help it grip its target receptor tightly.

That target is the growth hormone secretagogue receptor type 1a (GHS-R1a) — better known as the ghrelin receptor. (“Secretagogue” just means something that triggers a gland to release a hormone.) The receptor sits on the growth-hormone-producing cells of the pituitary (a small hormone gland at the base of the brain) and in the hypothalamus (a brain region that helps run the hormone system). By switching this receptor on, GHRP-2 imitates ghrelin — the so-called hunger hormone — and boosts the body’s natural bursts of growth hormone. It works alongside the body’s own growth-hormone-releasing hormone, and it partly cancels out somatostatin, the signal that normally puts the brakes on growth hormone release.

One important catch: GHRP-2 does not act on growth hormone alone. It also modestly raises ACTH and cortisol (stress hormones), nudges prolactin (a hormone best known for milk production) upward, and stirs up appetite through those same ghrelin pathways. These off-target effects show up in human pharmacology studies, and any honest look at the risks has to include them.

The claims

There is one legitimate, well-studied use: as a growth-hormone provocation test. A single dose given into a vein produces a reliable, repeatable spike in growth hormone, which lets doctors test for a deficiency without the low-blood-sugar danger of the older insulin tolerance test. This is the approved use in Japan.

Past that, the story splits in two. Decades ago, GHRP-2 was studied as a treatment for growth hormone deficiency and short stature in children, and as an appetite stimulant. Those research programs were mostly abandoned.

The gray-market claims — muscle gain, fat loss, anti-aging, better sleep, faster recovery, injury healing — are not supported by any trials that actually measured those results. One vendor has pointed to a “Phase III randomized placebo-controlled study for age-related changes in form, function and quality of life,” but no such trial turns up on ClinicalTrials.gov or in the peer-reviewed literature. Treat that as unverified marketing copy.

The evidence

The strongest human data are about the diagnostic use. A 2007 study by Chihara and colleagues in the European Journal of Endocrinology tested 77 healthy subjects and 58 patients with confirmed growth hormone deficiency, using a single 100 µg dose into a vein. It set a peak growth-hormone cutoff for diagnosing deficiency in adults (about 15 µg/L; the same threshold recalibrated to a recombinant WHO standard works out to about 9 µg/L — a recalibration, not a separate “severe” cutoff). This study is the basis for the Japanese approval.

On the hormone side, a 1997 study by Arvat and colleagues in Peptides gave GHRP-2 to six healthy young adults. It triggered a bigger growth hormone response than growth-hormone-releasing hormone did, plus comparable rises in ACTH and cortisol and a mild bump in prolactin — the clearest record of those off-target hormone effects. But the group was tiny, and it only measured hormone levels, not real-world health outcomes.

On appetite, a 2005 crossover study by Laferrère and colleagues in the Journal of Clinical Endocrinology and Metabolism infused GHRP-2 into seven lean healthy men. Food intake rose by about 36% compared with a saline placebo, alongside a clear growth hormone rise. Again: very small, very short-term, and measuring a stand-in marker rather than a lasting outcome.

The treatment studies in growth-hormone-deficient children are the most revealing. A 1998 Phase I study (10 children) mapped the growth hormone response and found a short half-life (how quickly the body clears the drug). An 8-month study of six children that same year found dose-dependent overnight growth hormone and faster growth during treatment — but IGF-I and IGFBP-3 (blood markers that usually track growth hormone’s effects) did not rise, there was no comparison group, and everyone knew they were getting the drug (open-label). A 12-month study of oral GHRP-2 in 10 children found increased appetite in seven of them during the first six months, but no meaningful change in BMI. Per the 2004 Drugs R&D record, the US Phase II program for growth hormone deficiency (run by Wyeth) appears to have been discontinued.

Animal studies — funded by Kaken, the Japanese developer — showed GHRP-2 released growth hormone more strongly than growth-hormone-releasing hormone in rats and dogs, and was harder for somatostatin to suppress. That fits the mechanism, but it is no substitute for human outcome data.

What is missing is the most important part. There are no repeated randomized controlled trials measuring the things that actually matter — body composition, strength, fractures, frailty, day-to-day function, or survival. The human treatment trials are small (single-digit numbers of people), old, often uncontrolled, and built on stand-in markers rather than real outcomes. There is also a conflict-of-interest flag worth naming: the person who discovered the peptide is an author on much of the foundational human work, and the animal studies were industry-funded.

That is why the overall evidence grade here is Preliminary human. Real human data on how the drug behaves do exist, so this is well past “animal only” or “theoretical.” But only the diagnostic use comes close to being established. The therapeutic and anti-aging claims sit much nearer to having no credible evidence at all.

Safety and side effects

At single diagnostic doses, GHRP-2 was generally well tolerated in published studies. The documented effects are exactly the ones its mechanism predicts: more appetite, and brief, non-specific rises in ACTH, cortisol, and prolactin (Arvat 1997). In the pediatric treatment studies, appetite rose without a meaningful change in BMI, and no toxic effects showed up over eight months in six children — but those groups are far too small to call anything safe.

Longer-term concerns are mostly theoretical, simply because they have not been studied well in humans. Keeping growth hormone and IGF-1 elevated over time carries the usual growth-hormone risks: insulin resistance and blood sugar shifts, fluid retention, carpal-tunnel-type symptoms, and joint problems. Repeatedly poking cortisol and prolactin adds more unknowns. Long-term, unsupervised use — the reality of the gray market — has essentially no controlled safety data behind it. On top of that, product sold outside an approved supply chain carries real purity and identity risks that have nothing to do with the molecule itself.

Legal and regulatory status

In the United States, GHRP-2 is not approved for any use and never went through FDA approval. The FDA has sent warning letters about it, saying that drug products compounded (custom-mixed by a pharmacy) with GHRP-2 do not qualify for the relevant compounding exemption — because it lacks a USP monograph (an official quality standard), is not part of any approved drug, and is not on the bulk substances list. Under the FDA’s earlier interim compounding framework, GHRP-2 was treated as Category 3 (nominated without adequate support or with safety concerns). The FDA dropped that Category 2/3 labeling scheme in January 2025.

There is an active 2026 FDA review of peptide compounding, with a PCAC meeting (a meeting of the FDA’s expert advisory committee) scheduled for July 2026 covering about a dozen peptides. GHRP-2 is not on that agenda — the list includes compounds such as BPC-157, KPV, TB-500, MOTS-C, and others. So while the rules for peptides are shifting broadly, that particular review does not directly cover GHRP-2. Anyone who needs the current status should check FDA postings directly.

In Japan, GHRP-2 has its only approval. Kaken Pharmaceutical markets it as a single-dose intravenous growth-hormone-stimulation diagnostic under the brand “GHRP Kaken.” Many secondary and vendor sources list an October 2004 approval date, but the 2004 Drugs R&D record from that time describes it as still awaiting approval, so the exact date is not firmly confirmed.

For athletes, GHRP-2 is banned by the World Anti-Doping Agency at all times, both in and out of competition, under Section S2 (peptide hormones, growth factors, and related substances), in the growth-hormone-releasing-factors subsection. It is named explicitly and is a non-specified substance.

Bottom line

GHRP-2 reliably does one thing in humans: it sets off a measurable pulse of growth hormone. That single trait has earned it a legitimate, approved spot as a diagnostic test in Japan, and the human pharmacology behind that use is solid. Everything else is thinner than the marketing suggests. The treatment studies are small, old, and largely uncontrolled; the programs that tried to turn it into a treatment for short stature were abandoned; and the popular claims about muscle, fat loss, and anti-aging rest on no outcome trials at all. It is banned in sport, not approved in the US, and sold in an unregulated market with real purity risks. The honest summary: GHRP-2 has a narrow proven use and a wide, unproven reputation.

Sources

• Pralmorelin — PubChem CID 5493556
• Pralmorelin — NCATS Inxight Drugs
• Development and regulatory record (Drugs R&D 2004, PMID 15230633)
• Adult diagnostic validation (Chihara, Eur J Endocrinol 2007, PMID 17609397)
• Endocrine pharmacodynamics and off-target hormones (Arvat, Peptides 1997, PMID 9285939)
• Appetite crossover study (Laferrère, JCEM 2005, PMID 15699539)
• Phase I pharmacokinetics in children (JCEM 1998, PMID 9543135)
• 8-month graded-dose study in GH-deficient children (JCEM 1998, PMID 9661608)
• 12-month oral GHRP-2 in GH-deficient children (JPEM 2003, PMID 14513874)
• KP-102 pharmacological characteristics (PMID 15646370)
• KP-102 general pharmacology (PMID 15646371)
• WADA Prohibited List
• WADA S2 — peptide hormones and growth factors (Drugs.com)
• FDA warning letter — Tailor Made Compounding (2020)
• FDA warning letter — United Pharmacy (2019)
• FDA 2026 peptide compounding context (FDA Law Blog)